Symbols / DRMA
DRMA Chart
About
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.03M |
| Enterprise Value | -3.34M | Income | -8.85M | Sales | — |
| Book/sh | 4.69 | Cash/sh | 4.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | 0.08 | Forward P/E | -0.33 | PEG | — |
| P/S | — | P/B | 0.27 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 4.20 |
| Current Ratio | 4.56 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 15.24 | EPS next Y | -3.87 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -96.45% |
| ROE | -203.36% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.20M |
| Shs Float | 494.30K | Short Float | 16.02% | Short Ratio | 0.15 |
| Short Interest | — | 52W High | 23.70 | 52W Low | 1.21 |
| Beta | 0.55 | Avg Volume | 1.54M | Volume | 140.29K |
| Target Price | $10.00 | Recom | None | Prev Close | $1.29 |
| Price | $1.26 | Change | -2.33% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.26
Latest analyst target
3. DCF / Fair value
$-35.04
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.26
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-21 | main | Maxim Group | Buy → Buy | $10 |
| 2025-05-21 | main | Maxim Group | Buy → Buy | $3 |
| 2024-08-21 | main | Maxim Group | Buy → Buy | $6 |
| 2023-03-23 | main | Maxim Group | — → Buy | $4 |
- DRMA Stock Price, Forecast & Analysis | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill Fri, 13 Feb 2026 08
- Dermata lines up as much as $12.4M to help launch OTC acne kit - Stock Titan Wed, 24 Dec 2025 08
- Dermata Therapeutics Expands At-The-Market Equity Offering Capacity - TipRanks ue, 27 Jan 2026 08
- 3.3M Australians with acne: Dermata's new treatment patent - Stock Titan ue, 20 Jan 2026 08
- 12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga Mon, 26 Jan 2026 08
- Dermata Therapeutics to implement 1-for-10 reverse stock split on August 1 - Investing.com Wed, 30 Jul 2025 07
- Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today? - Stocktwits Wed, 24 Dec 2025 08
- Responsive Playbooks and the DRMA Inflection - Stock Traders Daily Sun, 18 Jan 2026 08
- DRMA Stocks Thrive: Time for Action? - timothysykes.com Wed, 24 Dec 2025 08
- Dermata Therapeutics’ Skincare Innovation Sparks Interest​ - StocksToTrade Wed, 24 Dec 2025 08
- Can DRMA outperform in the next rally - July 2025 Snapshot & Weekly High Return Stock Forecasts - mfd.ru hu, 12 Feb 2026 10
- Dermata Therapeutics Announces Exercise of Warrants for $6.2 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules - Yahoo Finance hu, 27 Mar 2025 07
- Dermata Therapeutics (NASDAQ: DRMA) teases OTC brand, plans 2026 acne kit launch - Stock Titan hu, 04 Dec 2025 08
- Dermata stock surges after closing $4.1 million private placement - Investing.com Mon, 29 Dec 2025 08
- Dermata Therapeutics Raises Capital via December Private Placement - TipRanks Mon, 29 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 612745 | — | — | Stock Award(Grant) at price 0.00 per share. | PROEHL GERALD T | Chief Executive Officer | — | 2025-12-23 00:00:00 | I |
| 1 | 122549 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN HOOSE KYRI K | Chief Financial Officer | — | 2025-12-23 00:00:00 | D |
| 2 | 78741 | — | — | Stock Award(Grant) at price 0.00 per share. | HALE DAVID F | Director | — | 2025-01-23 00:00:00 | I |
| 3 | 196851 | — | — | Stock Award(Grant) at price 0.00 per share. | FISHER MARY | Director | — | 2025-01-21 00:00:00 | D |
| 4 | 78741 | — | — | Stock Award(Grant) at price 0.00 per share. | VAN HOOSE KYRI K | Chief Financial Officer | — | 2025-01-21 00:00:00 | D |
| 5 | 787402 | — | — | Stock Award(Grant) at price 0.00 per share. | PROEHL GERALD T | Chief Executive Officer | — | 2025-01-21 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -12.51M | -8.04M | -9.67M | -7.86M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -12.29M | -7.79M | -9.61M | -7.90M |
| ReconciledDepreciation | 0.00 | |||
| EBITDA | -12.51M | -8.04M | -9.67M | -7.86M |
| EBIT | -12.51M | -8.04M | -9.67M | -7.86M |
| NetInterestIncome | 225.78K | 247.22K | 63.57K | -45.61K |
| InterestExpense | -63.57K | 45.61K | ||
| InterestIncome | 225.78K | 247.22K | 63.57K | |
| NormalizedIncome | -12.29M | -7.79M | -9.61M | -7.90M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -12.29M | -7.79M | -9.61M | -7.90M |
| TotalExpenses | 12.51M | 8.04M | 9.67M | 7.86M |
| TotalOperatingIncomeAsReported | -12.51M | -8.04M | -9.67M | -7.86M |
| DilutedAverageShares | 152.98K | 19.49K | 4.60K | 1.79K |
| BasicAverageShares | 152.98K | 19.49K | 4.60K | 1.79K |
| DilutedEPS | -80.30 | -399.90 | -2.09K | -5.83K |
| BasicEPS | -80.30 | -399.90 | -2.09K | -5.83K |
| DilutedNIAvailtoComStockholders | -12.29M | -7.79M | -9.61M | -10.46M |
| NetIncomeCommonStockholders | -12.29M | -7.79M | -9.61M | -10.46M |
| PreferredStockDividends | 2.56M | |||
| NetIncome | -12.29M | -7.79M | -9.61M | -7.90M |
| NetIncomeIncludingNoncontrollingInterests | -12.29M | -7.79M | -9.61M | -7.90M |
| NetIncomeContinuousOperations | -12.29M | -7.79M | -9.61M | -7.90M |
| PretaxIncome | -12.29M | -7.79M | -9.61M | -7.90M |
| SpecialIncomeCharges | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 225.78K | 247.22K | 63.57K | -45.61K |
| TotalOtherFinanceCost | -63.57K | 45.61K | ||
| InterestExpenseNonOperating | -63.57K | 45.61K | ||
| InterestIncomeNonOperating | 225.78K | 247.22K | 63.57K | |
| OperatingIncome | -12.51M | -8.04M | -9.67M | -7.86M |
| OperatingExpense | 12.51M | 8.04M | 9.67M | 7.86M |
| ResearchAndDevelopment | 8.20M | 4.07M | 5.65M | 3.46M |
| SellingGeneralAndAdministration | 4.31M | 3.97M | 4.02M | 4.40M |
| GeneralAndAdministrativeExpense | 4.31M | 3.97M | 4.02M | 4.40M |
| OtherGandA | 4.31M | 3.97M | 4.02M | 4.40M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 251.78K | 26.20K | 5.13K | 3.47K |
| ShareIssued | 251.78K | 26.20K | 5.13K | 3.47K |
| TangibleBookValue | 1.56M | 6.36M | 6.02M | 10.11M |
| InvestedCapital | 1.56M | 6.36M | 6.02M | 10.11M |
| WorkingCapital | 1.56M | 6.36M | 6.02M | 10.11M |
| NetTangibleAssets | 1.56M | 6.36M | 6.02M | 10.11M |
| CommonStockEquity | 1.56M | 6.36M | 6.02M | 10.11M |
| TotalCapitalization | 1.56M | 6.36M | 6.02M | 10.11M |
| TotalEquityGrossMinorityInterest | 1.56M | 6.36M | 6.02M | 10.11M |
| StockholdersEquity | 1.56M | 6.36M | 6.02M | 10.11M |
| RetainedEarnings | -65.68M | -53.39M | -45.59M | -35.98M |
| AdditionalPaidInCapital | 67.24M | 59.74M | 51.61M | 46.09M |
| CapitalStock | 252.00 | 26.00 | 77.00 | 833.00 |
| CommonStock | 252.00 | 26.00 | 77.00 | 833.00 |
| TotalLiabilitiesNetMinorityInterest | 1.97M | 1.62M | 922.63K | 1.52M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 1.97M | 1.62M | 922.63K | 1.52M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 731.63K | 716.49K | 170.39K | 766.21K |
| PayablesAndAccruedExpenses | 1.24M | 907.13K | 752.25K | 750.63K |
| CurrentAccruedExpenses | 433.15K | 41.10K | 255.54K | 235.38K |
| InterestPayable | 0.00 | |||
| Payables | 808.01K | 866.03K | 496.70K | 515.25K |
| AccountsPayable | 808.01K | 866.03K | 496.70K | 515.25K |
| TotalAssets | 3.53M | 7.98M | 6.94M | 11.62M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.53M | 7.98M | 6.94M | 11.62M |
| OtherCurrentAssets | 14.50K | 11.60K | ||
| CurrentDeferredAssets | 0.00 | 55.72K | ||
| PrepaidAssets | 372.32K | 540.50K | 690.59K | 769.42K |
| Receivables | 8.36K | 12.60K | ||
| OtherReceivables | 12.60K | |||
| AccruedInterestReceivable | 8.36K | 12.60K | ||
| CashCashEquivalentsAndShortTermInvestments | 3.16M | 7.44M | 6.24M | 10.80M |
| CashAndCashEquivalents | 3.16M | 7.44M | 6.24M | 10.80M |
| CashFinancial | 10.80M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.16M | -6.41M | -8.83M | -5.69M |
| RepurchaseOfCapitalStock | -828.00 | -40.00 | 0.00 | -1.00M |
| RepaymentOfDebt | 0.00 | -556.48K | ||
| IssuanceOfDebt | 0.00 | 1.56M | ||
| IssuanceOfCapitalStock | 6.89M | 7.61M | 4.28M | 15.96M |
| InterestPaidSupplementalData | 0.00 | 1.42K | ||
| IncomeTaxPaidSupplementalData | 950.00 | 950.00 | 950.00 | 1.40K |
| EndCashPosition | 3.16M | 7.44M | 6.24M | 10.80M |
| BeginningCashPosition | 7.44M | 6.24M | 10.80M | 530.40K |
| ChangesInCash | -4.28M | 1.20M | -4.56M | 10.27M |
| FinancingCashFlow | 6.89M | 7.61M | 4.28M | 15.96M |
| CashFlowFromContinuingFinancingActivities | 6.89M | 7.61M | 4.28M | 15.96M |
| ProceedsFromStockOptionExercised | 1.11K | 187.00 | 287.00 | 0.00 |
| NetPreferredStockIssuance | 0.00 | -430.00K | ||
| PreferredStockPayments | 0.00 | -1.00M | ||
| PreferredStockIssuance | 0.00 | 570.00K | ||
| NetCommonStockIssuance | 6.89M | 7.61M | 4.28M | 15.39M |
| CommonStockPayments | -828.00 | -40.00 | 0.00 | |
| CommonStockIssuance | 6.89M | 7.61M | 4.28M | 15.39M |
| NetIssuancePaymentsOfDebt | 0.00 | 1.01M | ||
| NetShortTermDebtIssuance | 1.01M | |||
| ShortTermDebtPayments | -556.48K | |||
| ShortTermDebtIssuance | 1.56M | |||
| NetLongTermDebtIssuance | 0.00 | 1.01M | ||
| LongTermDebtPayments | 0.00 | -556.48K | ||
| LongTermDebtIssuance | 0.00 | 1.56M | ||
| OperatingCashFlow | -11.16M | -6.41M | -8.83M | -5.69M |
| CashFlowFromContinuingOperatingActivities | -11.16M | -6.41M | -8.83M | -5.69M |
| ChangeInWorkingCapital | 466.86K | 863.68K | -153.58K | 289.55K |
| ChangeInOtherCurrentLiabilities | 0.00 | |||
| ChangeInPayablesAndAccruedExpense | 298.68K | 700.98K | -275.52K | 1.04M |
| ChangeInAccruedExpense | 407.19K | 331.66K | -256.97K | 628.66K |
| ChangeInPayable | -108.51K | 369.33K | -18.54K | 410.97K |
| ChangeInAccountPayable | -108.51K | 369.33K | -18.54K | 410.97K |
| ChangeInPrepaidAssets | 168.18K | 162.69K | 121.94K | -750.08K |
| OtherNonCashItems | 14.13K | |||
| StockBasedCompensation | 657.65K | 522.08K | 930.33K | 1.91M |
| DepreciationAmortizationDepletion | 0.00 | |||
| DepreciationAndAmortization | 0.00 | |||
| Depreciation | 0.00 | |||
| NetIncomeFromContinuingOperations | -12.29M | -7.79M | -9.61M | -7.90M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for DRMA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|